丁苯酞序贯疗法联合双联抗血小板治疗对急性脑梗死患者血清HMGB1、MMP-9、3-MST、Fibulin-5的影响

Effects of sequential butylphthalide therapy and dual antiplatelet therapy on serum HMGB1,MMP-9,3-MST and Fibulin-5 in patients with acute cerebral infarction

目的分析急性脑梗死患者采用丁苯酞序贯疗法联合双联抗血小板进行治疗,对患者血清高迁移率族蛋白1(HMGB1)、金属基质蛋白酶-9(MMP-9)、3-巯基丙酮酸转硫酶(3-MST)、Fibulin-5的影响。方法120例急性脑梗死患者,随机分为常规组和观察组,每组60例。常规组采用常规治疗联合双联抗血小板治疗,观察组在常规组治疗基础上采用丁苯酞序贯疗法治疗。比较两组患者的血清HMGB1、MMP-9、3-MST、Fibulin-5水平及治疗满意度。结果治疗3、7、28 d后,观察组血清HMGB1、MMP-9、Fibulin-5水平均明显低于常规组,血清3-MST水平高于常规组,差异具有统计学意义(P<0.05)。观察组治疗总满意率为95.00%,明显高于常规组的80.00%,差异具有统计学意义(P<0.05)。结论对急性脑梗死患者采用丁苯酞序贯疗法联合双联抗血小板治疗,能够有效降低血清HMGB1、MMP-9、Fibulin-5水平,提高血清3-MST水平,使患者治疗满意度增加,值得临床应用推广。

Objective To analyze the effects of sequential butylphthalide therapy and dual antiplatelet therapy on serum high mobility group box 1(HMGB1),metal matrix protease-9(MMP-9),3-mercaptopyruvate transsulfurase(3-MST)and Fibulin-5 in patients with acute cerebral infarction.Methods A total of 120 patients with acute cerebral infarction were randomly divided into conventional group and observation group,with 60 cases in each group.The conventional group was treated with conventional therapy and dual antiplatelet therapy,and the observation group was treated with sequential butylphthalide therapy based on the conventional therapy.The serum HMGB1,MMP-9,3-MST,Fibulin-5 levels and treatment satisfaction were compared between the two groups.Results After 3,7 and 28 d of treatment,the serum HMGB1,MMP-9,Fibulin-5 levels of the observation group were obviously lower than those of the conventional group,and the serum 3-MST level was higher than that of the conventional group,and the difference was statistically significant(P<0.05).The total satisfaction rate with treatment of the observation group was 95.00%,which was obviously higher than 80.00%of the conventional group,and the difference was statistically significant(P<0.05).Conclusion Combination of sequential butylphthalide therapy and dual antiplatelet therapy can effectively reduce the levels of serum HMGB1,MMP-9,3-MST and Fibulin-5,improve the 3-MST,and increase the treatment satisfaction of the patients,which is worthy of clinical application and promotion.